Sartorius Stedim Biotech Introduces Advanced System for Agar and Membrane Transfer

Microsart® @media: Maximum Safety in Microbiological Quality Control

Goettingen, Germany | Aubagne, France, (PresseBox) - Sartorius Stedim Biotech (SSB), a leading global supplier for the pharmaceutical and biotech industries, is introducing Microsart @media to complement Microsart @vance, a product line for microbiological quality control in these sectors.

Microsart @media are agar media dishes for Microbial Limits Testing according to the USP (Chapter <61>) and EP (Chapter 2.6.12). They are pre-filled with various agar media types, such as Tryptic Soy Agar or R2A Agar, sterile packaged and ready-to-use in combination with Microsart @filter units. Moreover, the Microsart @media features an innovative patented lid that allows touch-free transfer of the filter membrane onto the media without using any tweezers. In addition, easy access to the colonies after incubation is given due to the liftable lid. The intelligent design and ease of use eliminates almost all handling mistakes.

The combination of Microsart @media and Microsart @filters introduce a brand-new agar and membrane transfer concept. Thanks to their concerted development the matching Microsart @media active lid fits perfectly onto the Microsart @filter base. The few steps required between sampling and incubation save time and labor, while delivering more reliable results. The touch-free membrane transfer eliminates membrane manipulation and handling, thereby minimizing a major source of secondary contamination.

Sartorius AG

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
The company employs approx. 3,000 people, and in 2012 earned sales revenue of 544.0 million euros.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Hitachi Vantara Labs beschleunigt Modell-Implementierung

Die Hi­t­a­chi Van­ta­ra Labs ha­ben neue Funk­tio­nen zur Ma­chi­ne-Lear­ning-Or­che­s­trie­rung vor­ge­s­tellt. Sie sol­len beim Über­prü­fen, Tes­ten, Neu-Trai­nie­ren und Re-Im­p­le­men­tie­ren von Mo­del­len in Pro­duk­ti­on­s­um­ge­bun­gen hel­fen.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.